A Novel Small Molecule Inhibitor of p38⍺ MAP Kinase Augments Cardiomyocyte Cell Cycle Entry in Response to Direct Cell Cycle Stimulation.

Riham R E AbouleisaJessica M MillerAhmad GebreilAbou Bakr M SalamaMarc DwengerHania AbdelhafezReham M WahidAdeniyi T AdewumiMahmoud E S SolimanNader E Abo-DyaTamer M A Mohamed

Published in: British journal of pharmacology (2023)

NDPPC is a novel inhibitor for p38 MAP kinase and is a promising drug to augment CM cell cycle response to the 4F. NDPPC could become an adjunct treatment with other cell cycle activators for heart failure treatment.

Keyphrases

cell cycle
cell proliferation
small molecule
heart failure
emergency department
protein kinase
atrial fibrillation
endothelial cells
electronic health record